Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 8
2004 6
2005 10
2006 19
2007 15
2008 27
2009 34
2010 33
2011 33
2012 27
2013 31
2014 29
2015 22
2016 34
2017 34
2018 51
2019 44
2020 50
2021 83
2022 64
2023 51
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

634 results

Results by year

Filters applied: . Clear all
Page 1
Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in Greece.
Kastritis E, Ntanasis-Stathopoulos I, Theodorakakou F, Migkou M, Roussou M, Malandrakis P, Kanellias N, Eleutherakis-Papaiakovou E, Fotiou D, Spiliopoulou V, Gavriatopoulou M, Patel S, Majer I, Boukis C, Fetani A, Dimopoulos MA, Terpos E. Kastritis E, et al. Among authors: terpos e. Clin Lymphoma Myeloma Leuk. 2024 Mar 19:S2152-2650(24)00110-1. doi: 10.1016/j.clml.2024.03.003. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38616479
Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin.
Efentakis P, Choustoulaki A, Kwiatkowski G, Varela A, Kostopoulos IV, Tsekenis G, Ntanasis-Stathopoulos I, Georgoulis A, Vorgias CE, Gakiopoulou H, Briasoulis A, Davos CH, Kostomitsopoulos N, Tsitsilonis O, Dimopoulos MA, Terpos E, Chłopicki S, Gavriatopoulou M, Andreadou I. Efentakis P, et al. Among authors: terpos e. Basic Res Cardiol. 2024 Mar 23. doi: 10.1007/s00395-024-01046-0. Online ahead of print. Basic Res Cardiol. 2024. PMID: 38520533
Prognosis of COVID-19 severity using DERGA, a novel machine learning algorithm.
Asteris PG, Gandomi AH, Armaghani DJ, Kokoris S, Papandreadi AT, Roumelioti A, Papanikolaou S, Tsoukalas MZ, Triantafyllidis L, Koutras EI, Bardhan A, Mohammed AS, Naderpour H, Paudel S, Samui P, Ntanasis-Stathopoulos I, Dimopoulos MA, Terpos E. Asteris PG, et al. Among authors: terpos e. Eur J Intern Med. 2024 Mar 7:S0953-6205(24)00094-3. doi: 10.1016/j.ejim.2024.02.037. Online ahead of print. Eur J Intern Med. 2024. PMID: 38458880
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. Kiladjian JJ, et al. Among authors: terpos e. Ann Hematol. 2024 Mar 4. doi: 10.1007/s00277-024-05665-4. Online ahead of print. Ann Hematol. 2024. PMID: 38438627
Single-cell analysis of MYD88L265P and MYD88WT Waldenström macroglobulinemia patients.
Bagratuni T, Aktypi F, Theologi O, Sakkou M, Verrou KM, Mavrianou-Koutsoukou N, Patseas D, Liacos C, Skourti S, Papadimou A, Taouxi K, Theodorakakou F, Kollias G, Sfikakis P, Terpos E, Dimopoulos MA, Kastritis E. Bagratuni T, et al. Among authors: terpos e. Hemasphere. 2024 Feb 8;8(2):e27. doi: 10.1002/hem3.27. eCollection 2024 Feb. Hemasphere. 2024. PMID: 38435423 Free PMC article.
Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patients.
Papatsirou M, Kontos CK, Ntanasis-Stathopoulos I, Malandrakis P, Sideris DC, Fotiou D, Liacos CI, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E. Papatsirou M, et al. Among authors: terpos e. Hemasphere. 2024 Jan 26;8(1):e34. doi: 10.1002/hem3.34. eCollection 2024 Jan. Hemasphere. 2024. PMID: 38434522 Free PMC article.
Small RNA-seq and clinical evaluation of tRNA-derived fragments in multiple myeloma: Loss of mitochondrial i-tRFHisGTG results in patients' poor treatment outcome.
Soureas K, Papadimitriou MA, Malandrakis P, Papanota AM, Adamopoulos PG, Ntanasis-Stathopoulos I, Liacos CI, Gavriatopoulou M, Sideris DC, Kastritis E, Dimopoulos MA, Scorilas A, Terpos E, Avgeris M. Soureas K, et al. Among authors: terpos e. Br J Haematol. 2024 Feb 27. doi: 10.1111/bjh.19332. Online ahead of print. Br J Haematol. 2024. PMID: 38414235
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Mateos MV, Weisel K, Terpos E, Delimpasi S, Kastritis E, Zamagni E, Delforge M, Ocio E, Katodritou E, Gay F, Larocca A, Leleu X, Otero PR, Schjesvold F, Cavo M, Dimopoulos MA. Mateos MV, et al. Among authors: terpos e. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284694. Online ahead of print. Haematologica. 2024. PMID: 38385280 Free article.
634 results